RecruitingPhase 1NCT07213791
Oncology
Cholangiocarcinoma
205
studies recruiting now
as of 7 Sept 2026
1,090
studies registered in total
as of 7 Sept 2026
9
countries with a recruiting site
as of 7 Sept 2026
24 Aug 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT07359820
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
RecruitingPhase 2NCT07780838
Cyclical Gemcitabine, Cisplatin, and Durvalumab Alternating With Pemigatinib for the Treatment of Unresectable, Locally Advanced or Metastatic Biliary Tract Cancers With FGFR2 Alterations
RecruitingPhase 2NCT05286814
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
RecruitingPhase 2NCT06728410
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 205 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Cholangiocarcinoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Cholangiocarcinoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (BRCA1, BRCA2, ROS1, PTPN3).
Treatments being studied
6 approved treatments and 62 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Pemigatinib (Pemazyre)Approved: Ivosidenib (Tibsovo)Approved: InfigratinibApproved: Futibatinib (Lytgobi)Approved: Zenocutuzumab (Bizengri)Approved: Infigratinib Phosphate (Truseltiq)
Phase 3Tegafur (Citofur)
Phase 3Gimeracil (Gimeracil component of teysuno)
Phase 3Cisplatin (Cisplatin)
Phase 3Capecitabine (Capecitabine)
Phase 3Oteracil
Phase 3Gemcitabine (Gemzar)
Phase 3Oxaliplatin (Eloxatin)
Phase 3Tinengotinib
+ 54 more in development
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).